Insulin Lispro vs Omentin-1
Head-to-head comparison of Insulin Lispro (Insulin lispro (B28-Lys, B29-Pro human insulin analog)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Insulin Lispro | Omentin-1 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Insulin lispro (B28-Lys, B29-Pro human insulin analog) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 5808.0 Da | ~35 kDa |
| Half-Life | About 1 hour | hours |
| Amino Acids | 51 | 313 |
| Typical Dose | 0.05-0.2 U/kg per meal | No approved human dose; research use only |
| Route | Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 12000 | 82 |
| Research Status | Approved | Pre-clinical |
Insulin Lispro Benefits
- ✓Rapid postprandial glucose control
- ✓Flexible premeal timing
- ✓Predictable onset of action
- ✓Useful in basal-bolus regimens
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Insulin Lispro Dosing
Inject SC 0-15 minutes before meals|Adjust dose to carbohydrate intake and premeal glucose|Often paired with a basal insulin
Omentin-1 Dosing
not established|not established
Insulin Lispro Side Effects
- ⚠Hypoglycemia
- ⚠Weight gain
- ⚠Injection-site reactions
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Insulin Lispro
Clinical studies show faster onset and shorter duration than regular insulin, improving post-meal glucose control. It is a standard comparator in diabetes pharmacology and closed-loop insulin-delivery research.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.